Episode Player
OPTISCAN IMAGING LTD (OIL) - Real-Time Digital Pathology From A Pen-Sized Scanner
ASX BRIEFS
A pen-sized microscope that can see living tissue in real time sounds like science fiction, but it’s exactly what Optiscan Imaging Limited is building. We welcome back Dr Camile Farah to talk through the company’s confocal laser endomicroscopy platform and why real-time digital pathology could change the way surgery, cancer care, and veterinary medicine make decisions at the point of care.
We dig into Optiscan’s latest regulatory milestone: the US FDA dossier submission for InSpecta®, a portable veterinary imaging device designed for clinic and field use. Camile explains why the US market matters so much, why veterinary is a smart entry point with a lower barrier than human healthcare, and how that step can de-risk the broader FDA pathway. If you’re tracking ASX medical device stories, this is a clear look at how regulatory strategy links directly to commercial readiness and revenue timing.
From there, we move to human health and a world-first in-human head and neck cancer imaging study at St John of God Murdoch Hospital, combining the InVue® precision surgery device with the InForm® Digital Pathology Platform. The core promise is simple and powerful: help surgeons and pathologists assess margins and tissue features in real time, cutting down the anxious wait for lab reports and reducing the risk of a second surgery. We also cover the partnership with Australian Clinical Labs and how telepathology streaming could enable fast expert reads across distance, much like teleradiology did for medical imaging.
If you want practical insight into real-time pathology, telepathology, FDA submissions, and the commercial triggers ahead, listen now. Subscribe to ASX Briefs, share the episode with a colleague, and leave a review with your biggest question about live microscopic imaging in theatre.
